陽光諾和(688621.SH):擬購買朗研生命100%股權 將增加醫藥工業板塊業務
格隆匯5月12日丨陽光諾和(688621.SH)公佈,公司擬通過發行股份及可轉換公司債券方式,購買利虔、朗頤投資等38名朗研生命全體股東持有的朗研生命100%股權,並向不超過35名特定投資者發行股份募集配套資金。截至本預案簽署之日,與本次交易相關的審計、評估工作尚未完成,本次交易標的資產交易價格尚未確定。
本次收購朗研生命的交易,能夠明顯提高上市公司行業競爭力和盈利能力,完善上市公司的戰略佈局,對上市公司主營業務的主要影響如下:一方面,公司能夠實現自主研發產品的孵化和實施,充分發揮陽光諾和的研發優勢和朗研生命的生產銷售優勢,促進陽光諾和研發品種落地以及朗研生命產能釋放,形成公司新的盈利增長點。另一方面,公司將增加醫藥工業板塊業務,實現“CRO+醫藥工業”的產業佈局。未來,醫藥工業板塊將成爲公司主營業務的重要組成部分,進一步提高上市公司盈利能力及抗風險能力,促進上市公司的可持續發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.